药学干预在老年慢性病患者中的应用效果  

Application Effect of Pharmaceutical Intervention in Elderly Patients with Chronic Diseases

作　　者：李瑞华 Li Ruihua(Pharmacy Department,Shanghai Putuo District People's Hospital,Shanghai 200051,China)

机构地区：[1]上海市普陀区人民医院药剂科,上海200051

出　　处：《中国社区医师》2025年第6期9-11,共3页Chinese Community Doctors

摘　　要：目的:探讨药学干预老年慢性病患者中的应用效果。方法:选取2021年6月—2022年12月上海市普陀区人民医院收治的80例老年慢性病患者作为研究对象,随机分为两组,每组40例。对照组接受常规干预,研究组接受药学干预。对比两组不良反应发生情况、药物知识认知情况、依从性及生活质量。结果:研究组不良反应总发生率低于对照组(P=0.021)。研究组不可擅自改药、用药剂量和频率、用药配伍禁忌、用药不良反应、用药时间、药物作用评分均高于对照组(P<0.05)。研究组用药依从率高于对照组(P=0.026)。干预后,两组生活质量评分均高于干预前,且研究组高于对照组(P<0.05)。结论:药学干预在老年慢性病患者中的应用效果较好,能够降低不良反应发生率,提高患者的药物知识认知水平和依从性,改善其生活质量。Objective:To investigate the application effect of pharmaceutical intervention in elderly patients with chronic disease.Methods:A total of 80 elderly patients with chronic diseases admitted to Shanghai Putuo District People's Hospital from June 2021 to December 2022 were selected as the study subjects.They were randomly divided into two groups,with 40 cases in each group.The control group received conventional intervention,and the study group received pharmaceutical intervention.The occurrence of adverse reactions,drug knowledge cognition,compliance and quality of life were compared between the two groups.Results:The total incidence of adverse reactions in the study group was lower than that in the control group(P=0.021).The forbidden medication change without authorization,dosage and frequency,drug incompatibility,adverse drug reactions,medication duration,and drug effect scores in the study group were higher than those in the control group(P<0.05).The medication compliance rate in the study group was higher than that in the control group(P=0.026).After intervention,the quality of life scores in two groups were higher than those before intervention,and the score in the study group was higher than that in the control group(P<0.05).Conclusion:Pharmaceutical intervention has a good application effect in elderly patients with chronic disease,and can reduce the incidence of adverse reactions,enhance the drug knowledge recognition level and compliance of patients,and improve their quality of life.

关 键 词：药学干预 老年 慢性病 

分 类 号：R969.3[医药卫生—药理学]